A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer

Summary

The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of the combination of JNJ-87189401 and JNJ-78278343 is, with or without apalutamide. Part 3 of this study evaluates the safety of the triplet combination of JNJ-87189401 and JNJ-78278343 with standard of care (SOC) lutetium Lu-177 vipivotide tetraxetan. Part 4 of this study further evaluates the safety of the triplet combination of JNJ-87189401 and JNJ-78278343 with JNJ-101556143 in participants with advanced prostate cancer.

Eligibility

Age range

18+ years

Sex

Male

Healthy volunteers

No

Interventions

• Drug
  JNJ-78278343

  JNJ-78278343 will be administered.

• Drug
  JNJ-87189401

  JNJ-87189401 will be administered.

• Drug
  Apalutamide

  Apalutamide will be administered.

• Drug
  Lutetium Lu-177 Vipivotide Tetraxetan

  Lutetium Lu-177 Vipivotide Tetraxetan will be administered as SOC treatment.

• Drug
  JNJ-101556143

  JNJ-101556143 will be administered.

Locations (13)